A Haplotype of the Human CXCR1 Gene Protective Against Rapid Disease Progression in HIV-1+ Patients

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.0611670104
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

P04-50 LB. Prevalence of Cross-Reactive HIV-1 Neutralizing Activity in HIV-1 Infected Patients With Rapid or Slow Disease Progression

Retrovirology
VirologyInfectious Diseases
2009English

Antibody Against Human Immunodeficiency Virus Type 1 (HIV-1) Tat Protein May Have Influenced the Progression of AIDS in HIV-1-infected Hemophiliac Patients.

Clinical and diagnostic laboratory immunology
1996English

Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia

PLoS Genetics
EvolutionEcologyGeneticsMolecular BiologyCancer ResearchSystematicsBehavior
2016English

Haplotype Analysis of the SDF-1 (CXCL12) Gene in a Longitudinal HIV-1/AIDS Cohort Study

Genes and Immunity
ImmunologyGenetics
2005English

Emergence of CXCR4-tropic HIV-1 Variants Followed by Rapid Disease Progression in Hemophiliac Slow Progressors

PLoS ONE
Multidisciplinary
2017English

Variants in ZNRD1 Gene Predict HIV-1/AIDS Disease Progression in a Han Chinese Population in Taiwan

PLoS ONE
Multidisciplinary
2013English

Novel Haplotype Indicator for End-Stage Renal Disease Progression Among Saudi Patients

International Journal of Nephrology
Nephrology
2019English

The Performance of a Rapid Human Immunodeficiency Virus (HIV) Assay - Genie II HIV-1/HIV-2 in the Screening of HIV

Journal of High Institute of Public Health
2008English

Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor

Journal of Clinical Microbiology
Microbiology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy